# Trevena

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trevena

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.trevena.com
- Total disclosed funding: $125M
- Latest round: Series C (May 9, 2013)
- Investors on record: 6

## About

Trevena, Inc. is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, with a primary emphasis on pain management and neurological conditions.Founded in 2007 in the United States, Trevena, Inc. specializes in biopharmaceuticals, particularly in developing medications for CNS disorders. The company held its IPO in January 2014, raising USD 64.75 mn by selling 9.25 million shares at USD 7 each. In December 2014, Trevena raised an additional USD 45 mn through a private placement of 11.25 million shares. The company's current CEO is Carrie Bourdow.Trevena, Inc. primarily focuses on developing innovative biopharmaceutical products aimed at treating central nervous system (CNS) disorders. The company's core offering is OLINVYK® (oliceridine) injection, an FDA-approved medication designed for managing acute pain, especially in hospital settings. Trevena's pipeline includes investigational candidates such as TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for acute migraine, and TRV734 for opioid use disorder, all developed from Nobel Prize-winning research. These products are marketed primarily to healthcare professionals and patients in the United States.Trevena, Inc. generated revenue of USD 3.125 bn in the most recent year, 2023, primarily through the sale of OLINVYK® to hospitals and healthcare providers. The company uses a direct sales model, leveraging partnerships with distributors to enhance market penetration. While the availability of investigational drugs depends on FDA approval, the financial performance remains closely tied to the adoption of OLINVYK® in clinical settings.Trevena is looking to expand its product offerings, with plans to launch new investigational drugs targeting various CNS disorders. The company aims to penetrate new markets, particularly expanding its reach within the United States and exploring opportunities in international markets. The funding raised in the most recent deals, totaling USD 80 mn, will support these initiatives, allowing for increased research and development efforts and the potential launch of new products before the end of 2024.

## Funding rounds

- Series C, May 9, 2013, $60M — Alta Partners, HealthCare Ventures, New Enterprise Associates, Polaris Partners, Yasuda Enterprise Development, Forest Laboratories, Inc.
- Series B, Dec 15, 2011, $3.2M — Polaris Partners
- Series B, Jul 1, 2011, $2.4M — Polaris Partners
- Series B, Jul 14, 2010, $35M — Alta Partners, HealthCare Ventures, New Enterprise Associates, Polaris Partners
- Series A, Jun 30, 2009, $11M — Alta Partners, HealthCare Ventures, New Enterprise Associates, Polaris Partners
- Series A, Sep 30, 2008, $8M — Polaris Partners
- Series A, Jan 31, 2008, $5M — Alta Partners, HealthCare Ventures, New Enterprise Associates, Polaris Partners

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A, Series B, Series C
- HealthCare Ventures — Series A, Series B, Series C
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B, Series C
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B, Series C
- Yasuda Enterprise Development (https://capitalatlas.ai/funds/yasuda-enterprise-development) — Series C
- Forest Laboratories, Inc. — Series C